The epidemiological impact of childhood influenza vaccination using live-attenuated influenza vaccine (LAIV) in Germany: predictions of a simulation study

Rose MA, Damm O, Greiner W, Knuf M, Wutzler P, Liese JG, Krüger H, Wahn U, Schaberg T, Schwehm M, Kochmann TF, et al. (2014)
BMC Infectious Diseases 14(1).

Download
OA
Journal Article | Published | English
Author
; ; ; ; ; ; ; ; ; ; ;
All
Abstract
Background Routine annual influenza vaccination is primarily recommended for all persons aged 60 and above and for people with underlying chronic conditions in Germany. Other countries have already adopted additional childhood influenza immunisation programmes. The objective of this study is to determine the potential epidemiological impact of implementing paediatric influenza vaccination using intranasally administered live-attenuated influenza vaccine (LAIV) in Germany. Methods A deterministic age-structured model is used to simulate the population-level impact of different vaccination strategies on the transmission dynamics of seasonal influenza in Germany. In our base-case analysis, we estimate the effects of adding a LAIV-based immunisation programme targeting children 2 to 17 years of age to the existing influenza vaccination policy. The data used in the model is based on published evidence complemented by expert opinion. Results In our model, additional vaccination of children 2 to 17 years of age with LAIV leads to the prevention of 23.9 million influenza infections and nearly 16 million symptomatic influenza cases within 10 years. This reduction in burden of disease is not restricted to children. About one third of all adult cases can indirectly be prevented by LAIV immunisation of children. Conclusions Our results demonstrate that vaccinating children 2–17 years of age is likely associated with a significant reduction in the burden of paediatric influenza. Furthermore, annual routine childhood vaccination against seasonal influenza is expected to decrease the incidence of influenza among adults and older people due to indirect effects of herd protection. In summary, our model provides data supporting the introduction of a paediatric influenza immunisation programme in Germany.
Publishing Year
ISSN
Financial disclosure
Article Processing Charge funded by the Deutsche Forschungsgemeinschaft and the Open Access Publication Fund of Bielefeld University.
PUB-ID

Cite this

Rose MA, Damm O, Greiner W, et al. The epidemiological impact of childhood influenza vaccination using live-attenuated influenza vaccine (LAIV) in Germany: predictions of a simulation study. BMC Infectious Diseases. 2014;14(1).
Rose, M. A., Damm, O., Greiner, W., Knuf, M., Wutzler, P., Liese, J. G., Krüger, H., et al. (2014). The epidemiological impact of childhood influenza vaccination using live-attenuated influenza vaccine (LAIV) in Germany: predictions of a simulation study. BMC Infectious Diseases, 14(1).
Rose, M. A., Damm, O., Greiner, W., Knuf, M., Wutzler, P., Liese, J. G., Krüger, H., Wahn, U., Schaberg, T., Schwehm, M., et al. (2014). The epidemiological impact of childhood influenza vaccination using live-attenuated influenza vaccine (LAIV) in Germany: predictions of a simulation study. BMC Infectious Diseases 14.
Rose, M.A., et al., 2014. The epidemiological impact of childhood influenza vaccination using live-attenuated influenza vaccine (LAIV) in Germany: predictions of a simulation study. BMC Infectious Diseases, 14(1).
M.A. Rose, et al., “The epidemiological impact of childhood influenza vaccination using live-attenuated influenza vaccine (LAIV) in Germany: predictions of a simulation study”, BMC Infectious Diseases, vol. 14, 2014.
Rose, M.A., Damm, O., Greiner, W., Knuf, M., Wutzler, P., Liese, J.G., Krüger, H., Wahn, U., Schaberg, T., Schwehm, M., Kochmann, T.F., Eichner, M.: The epidemiological impact of childhood influenza vaccination using live-attenuated influenza vaccine (LAIV) in Germany: predictions of a simulation study. BMC Infectious Diseases. 14, (2014).
Rose, Markus A, Damm, Oliver, Greiner, Wolfgang, Knuf, Markus, Wutzler, Peter, Liese, Johannes G, Krüger, Hagen, Wahn, Ulrich, Schaberg, Tom, Schwehm, Markus, Kochmann, Thomas F, and Eichner, Martin. “The epidemiological impact of childhood influenza vaccination using live-attenuated influenza vaccine (LAIV) in Germany: predictions of a simulation study”. BMC Infectious Diseases 14.1 (2014).
Main File(s)
Access Level
OA Open Access
Last Uploaded
2014-03-04 10:35:29

This data publication is cited in the following publications:
This publication cites the following data publications:

6 Citations in Europe PMC

Data provided by Europe PubMed Central.

Cost-effectiveness analysis of the direct and indirect impact of intranasal live attenuated influenza vaccination strategies in children: alternative country profiles.
Gibson E, Begum N, Martinon-Torres F, Safadi MA, Sackeyfio A, Hackett J, Rajaram S., J Mark Access Health Policy 4(), 2016
PMID: 27429720
Modeling infectious disease dynamics in the complex landscape of global health.
Heesterbeek H, Anderson RM, Andreasen V, Bansal S, De Angelis D, Dye C, Eames KT, Edmunds WJ, Frost SD, Funk S, Hollingsworth TD, House T, Isham V, Klepac P, Lessler J, Lloyd-Smith JO, Metcalf CJ, Mollison D, Pellis L, Pulliam JR, Roberts MG, Viboud C; Isaac Newton Institute IDD Collaboration, Arinaminpathy N, Ball F, Bogich T, Gog J, Grenfell B, Lloyd AL, Mclean A, O'Neill P, Pearson C, Riley S, Tomba GS, Trapman P, Wood J., Science 347(6227), 2015
PMID: 25766240
Public health impact and cost-effectiveness of intranasal live attenuated influenza vaccination of children in Germany.
Damm O, Eichner M, Rose MA, Knuf M, Wutzler P, Liese JG, Kruger H, Greiner W., Eur J Health Econ 16(5), 2015
PMID: 24859492

41 References

Data provided by Europe PubMed Central.

Efficacy and safety of a live attenuated, cold-adapted influenza vaccine, trivalent against culture-confirmed influenza in young children in Asia.
Tam JS, Capeding MR, Lum LC, Chotpitayasunondh T, Jiang Z, Huang LM, Lee BW, Qian Y, Samakoses R, Lolekha S, Rajamohanan KP, Narayanan SN, Kirubakaran C, Rappaport R, Razmpour A, Gruber WC, Forrest BD; Pan-Asian CAIV-T Pediatric Efficacy Trial Network., Pediatr. Infect. Dis. J. 26(7), 2007
PMID: 17596805
Vaccines for preventing influenza in the elderly
AUTHOR UNKNOWN, 2010
Comparative efficacy of inactivated and live attenuated influenza vaccines.
Monto AS, Ohmit SE, Petrie JG, Johnson E, Truscon R, Teich E, Rotthoff J, Boulton M, Victor JC., N. Engl. J. Med. 361(13), 2009
PMID: 19776407
Vaccination coverage rates in eleven European countries during two consecutive influenza seasons.
Blank PR, Schwenkglenks M, Szucs TD., J. Infect. 58(6), 2009
PMID: 19446340

AUTHOR UNKNOWN, 2009
Incidence of influenza and associated illness in children aged 0-19 years: a systematic review.
Bueving HJ, van der Wouden JC, Berger MY, Thomas S., Rev. Med. Virol. 15(6), 2005
PMID: 16178047

AUTHOR UNKNOWN, 2011

AUTHOR UNKNOWN, 2007
Economic evidence of influenza vaccination in children.
Savidan E, Chevat C, Marsh G., Health Policy 86(2-3), 2008
PMID: 18054109
Public health and economic benefits of new pediatric influenza vaccination programs in Argentina.
Giglio N, Gentile A, Lees L, Micone P, Armoni J, Reygrobellet C, Crepey P., Hum Vaccin Immunother 8(3), 2012
PMID: 22330959
Oil-in-water emulsion adjuvant with influenza vaccine in young children.
Vesikari T, Knuf M, Wutzler P, Karvonen A, Kieninger-Baum D, Schmitt HJ, Baehner F, Borkowski A, Tsai TF, Clemens R., N. Engl. J. Med. 365(15), 2011
PMID: 21995388

Export

0 Marked Publications

Open Data PUB

Web of Science

View record in Web of Science®

Sources

PMID: 24450996
PubMed | Europe PMC

Search this title in

Google Scholar